2023-04-012024-03-312024-03-31false02236368SVP HEALTH CARE LIMITED2024-08-1487300iso4217:GBPxbrli:pure022363682023-04-01022363682024-03-31022363682023-04-012024-03-31022363682022-04-01022363682023-03-31022363682022-04-012023-03-3102236368bus:SmallEntities2023-04-012024-03-3102236368bus:AuditExempt-NoAccountantsReport2023-04-012024-03-3102236368bus:FullAccounts2023-04-012024-03-3102236368bus:PrivateLimitedCompanyLtd2023-04-012024-03-3102236368core:WithinOneYear2024-03-3102236368core:AfterOneYear2024-03-3102236368core:WithinOneYear2023-03-3102236368core:AfterOneYear2023-03-3102236368core:ShareCapital2024-03-3102236368core:SharePremium2024-03-3102236368core:RevaluationReserve2024-03-3102236368core:OtherReservesSubtotal2024-03-3102236368core:RetainedEarningsAccumulatedLosses2024-03-3102236368core:ShareCapital2023-03-3102236368core:SharePremium2023-03-3102236368core:RevaluationReserve2023-03-3102236368core:OtherReservesSubtotal2023-03-3102236368core:RetainedEarningsAccumulatedLosses2023-03-3102236368core:LandBuildings2024-03-3102236368core:PlantMachinery2024-03-3102236368core:Vehicles2024-03-3102236368core:FurnitureFittings2024-03-3102236368core:OfficeEquipment2024-03-3102236368core:NetGoodwill2024-03-3102236368core:IntangibleAssetsOtherThanGoodwill2024-03-3102236368core:ListedExchangeTraded2024-03-3102236368core:UnlistedNon-exchangeTraded2024-03-3102236368core:LandBuildings2023-03-3102236368core:PlantMachinery2023-03-3102236368core:Vehicles2023-03-3102236368core:FurnitureFittings2023-03-3102236368core:OfficeEquipment2023-03-3102236368core:NetGoodwill2023-03-3102236368core:IntangibleAssetsOtherThanGoodwill2023-03-3102236368core:ListedExchangeTraded2023-03-3102236368core:UnlistedNon-exchangeTraded2023-03-3102236368core:LandBuildings2023-04-012024-03-3102236368core:PlantMachinery2023-04-012024-03-3102236368core:Vehicles2023-04-012024-03-3102236368core:FurnitureFittings2023-04-012024-03-3102236368core:OfficeEquipment2023-04-012024-03-3102236368core:NetGoodwill2023-04-012024-03-3102236368core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3102236368core:ListedExchangeTraded2023-04-012024-03-3102236368core:UnlistedNon-exchangeTraded2023-04-012024-03-3102236368core:MoreThanFiveYears2023-04-012024-03-3102236368core:Non-currentFinancialInstruments2024-03-3102236368core:Non-currentFinancialInstruments2023-03-3102236368dpl:CostSales2023-04-012024-03-3102236368dpl:DistributionCosts2023-04-012024-03-3102236368core:LandBuildings2023-04-012024-03-3102236368core:PlantMachinery2023-04-012024-03-3102236368core:Vehicles2023-04-012024-03-3102236368core:FurnitureFittings2023-04-012024-03-3102236368core:OfficeEquipment2023-04-012024-03-3102236368dpl:AdministrativeExpenses2023-04-012024-03-3102236368core:NetGoodwill2023-04-012024-03-3102236368core:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3102236368dpl:GroupUndertakings2023-04-012024-03-3102236368dpl:ParticipatingInterests2023-04-012024-03-3102236368dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-012024-03-3102236368core:ListedExchangeTraded2023-04-012024-03-3102236368dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-012024-03-3102236368core:UnlistedNon-exchangeTraded2023-04-012024-03-3102236368dpl:CostSales2022-04-012023-03-3102236368dpl:DistributionCosts2022-04-012023-03-3102236368core:LandBuildings2022-04-012023-03-3102236368core:PlantMachinery2022-04-012023-03-3102236368core:Vehicles2022-04-012023-03-3102236368core:FurnitureFittings2022-04-012023-03-3102236368core:OfficeEquipment2022-04-012023-03-3102236368dpl:AdministrativeExpenses2022-04-012023-03-3102236368core:NetGoodwill2022-04-012023-03-3102236368core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3102236368dpl:GroupUndertakings2022-04-012023-03-3102236368dpl:ParticipatingInterests2022-04-012023-03-3102236368dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3102236368core:ListedExchangeTraded2022-04-012023-03-3102236368dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3102236368core:UnlistedNon-exchangeTraded2022-04-012023-03-3102236368core:NetGoodwill2024-03-3102236368core:IntangibleAssetsOtherThanGoodwill2024-03-3102236368core:LandBuildings2024-03-3102236368core:PlantMachinery2024-03-3102236368core:Vehicles2024-03-3102236368core:FurnitureFittings2024-03-3102236368core:OfficeEquipment2024-03-3102236368core:AfterOneYear2024-03-3102236368core:WithinOneYear2024-03-3102236368core:ListedExchangeTraded2024-03-3102236368core:UnlistedNon-exchangeTraded2024-03-3102236368core:ShareCapital2024-03-3102236368core:SharePremium2024-03-3102236368core:RevaluationReserve2024-03-3102236368core:OtherReservesSubtotal2024-03-3102236368core:RetainedEarningsAccumulatedLosses2024-03-3102236368core:NetGoodwill2023-03-3102236368core:IntangibleAssetsOtherThanGoodwill2023-03-3102236368core:LandBuildings2023-03-3102236368core:PlantMachinery2023-03-3102236368core:Vehicles2023-03-3102236368core:FurnitureFittings2023-03-3102236368core:OfficeEquipment2023-03-3102236368core:AfterOneYear2023-03-3102236368core:WithinOneYear2023-03-3102236368core:ListedExchangeTraded2023-03-3102236368core:UnlistedNon-exchangeTraded2023-03-3102236368core:ShareCapital2023-03-3102236368core:SharePremium2023-03-3102236368core:RevaluationReserve2023-03-3102236368core:OtherReservesSubtotal2023-03-3102236368core:RetainedEarningsAccumulatedLosses2023-03-3102236368core:NetGoodwill2022-04-0102236368core:IntangibleAssetsOtherThanGoodwill2022-04-0102236368core:LandBuildings2022-04-0102236368core:PlantMachinery2022-04-0102236368core:Vehicles2022-04-0102236368core:FurnitureFittings2022-04-0102236368core:OfficeEquipment2022-04-0102236368core:AfterOneYear2022-04-0102236368core:WithinOneYear2022-04-0102236368core:ListedExchangeTraded2022-04-0102236368core:UnlistedNon-exchangeTraded2022-04-0102236368core:ShareCapital2022-04-0102236368core:SharePremium2022-04-0102236368core:RevaluationReserve2022-04-0102236368core:OtherReservesSubtotal2022-04-0102236368core:RetainedEarningsAccumulatedLosses2022-04-0102236368core:AfterOneYear2023-04-012024-03-3102236368core:WithinOneYear2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:CostValuation2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-012024-03-3102236368core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3102236368core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3102236368core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3102236368core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3102236368core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3102236368bus:Director12023-04-012024-03-3102236368bus:Director22023-04-012024-03-3102236368bus:Director32023-04-012024-03-3102236368bus:Director42023-04-012024-03-3102236368core:FurnitureFittingsToolsEquipment2023-03-3102236368core:FurnitureFittingsToolsEquipment2023-04-012024-03-3102236368core:FurnitureFittingsToolsEquipment2024-03-31

SVP HEALTH CARE LIMITED

Registered Number
02236368
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2024

SVP HEALTH CARE LIMITED
Company Information
for the year from 1 April 2023 to 31 March 2024

Directors

Pooja Dewan
Dr Sandeep Dewan
Sonia Dewan
Dr Vini Dewan

Company Secretary

Dr Vini Dewan

Registered Address

The Haining Melbury Road
Jesmond Park East
Newcastle Upon Tyne
NE7 7DE

Registered Number

02236368 (England and Wales)
SVP HEALTH CARE LIMITED
Statement of Financial Position
31 March 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets41,639,2111,684,716
Investment property5337,029337,029
1,976,2402,021,745
Current assets
Debtors635,76432,825
Cash at bank and on hand118,43261,640
154,19694,465
Creditors amounts falling due within one year7(174,640)(379,558)
Net current assets (liabilities)(20,444)(285,093)
Total assets less current liabilities1,955,7961,736,652
Provisions for liabilities8(10,721)(12,020)
Net assets1,945,0751,724,632
Capital and reserves
Called up share capital22
Profit and loss account1,945,0731,724,630
Shareholders' funds1,945,0751,724,632
The financial statements were approved and authorised for issue by the Board of Directors on 14 August 2024, and are signed on its behalf by:
Dr Sandeep Dewan
Director
Registered Company No. 02236368
SVP HEALTH CARE LIMITED
Notes to the Financial Statements
for the year ended 31 March 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to the Income Statement
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows: Goodwill - 20% straight line If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Goodwill
Goodwill arising on an acquisition of a business is carried at cost less accumulated impairment losses, if any. Goodwill is amortised over its expected useful life which is estimated to be ten years. Goodwill is assessed for impairment when there are indicators of impairment and any impairment is charged to the income statement. No reversals of impairment are recognised.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. The assets residual values, useful lives and depreciation methods are reviewed and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposal are determined by comparing the proceeds with the carrying amount and are recognised in the Income Statement Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)Straight line (years)
Land and buildings-50
Plant and machinery15-
Fixtures and fittings15-
Office Equipment-3
Investment property
Investment property is carried at fair value determined annually by external valuers and derived from the current market rents and investment property yields for comparable real estate. These values are adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided. Changes in fair value are recognised in the Income Statement.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
2.Average number of employees

20242023
Average number of employees during the year2525
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 April 2320,00020,000
At 31 March 2420,00020,000
Amortisation and impairment
At 01 April 2320,00020,000
At 31 March 2420,00020,000
Net book value
At 31 March 24--
At 31 March 23--
4.Tangible fixed assets

Land & buildings

Plant & machinery

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 April 232,005,58672,809161,2426,9632,246,600
Additions--3,449-3,449
At 31 March 242,005,58672,809164,6916,9632,250,049
Depreciation and impairment
At 01 April 23370,05967,508120,8673,450561,884
Charge for year40,1127046,4011,73748,954
At 31 March 24410,17168,212127,2685,187610,838
Net book value
At 31 March 241,595,4154,59737,4231,7761,639,211
At 31 March 231,635,5275,30140,3753,5131,684,716
5.Investment property

£
Fair value at 01 April 23337,029
At 31 March 24337,029
6.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables28,39225,047
Other debtors3,9624,727
Prepayments and accrued income3,4103,051
Total35,76432,825
7.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables14,6345,440
Taxation and social security111,48368,759
Other creditors25,306282,082
Accrued liabilities and deferred income23,21723,277
Total174,640379,558
8.Provisions for liabilities

2024

2023

££
Net deferred tax liability (asset)10,72112,020
Total10,72112,020
9.Related party transactions
During the year, the directors had a loan account with the company. As at 01/04/2023, the company owed the directors £267,531. During the year, the directors have had advances of £340,468 and have made repayments of £70,192. As at 31/03/2024, the directors owed the company £2,745. This loan is not interest bearing and will be repaid within nine months of the year end.